Pre-Clinical Research
Filter News
Found 8,681 articles
-
Nuvalent Presents New Preclinical Data Supporting Potential Best-in-Class Profile for ALK-Selective Inhibitor NVL-655 at IASLC 2022 World Conference on Lung Cancer Annual Meeting
8/5/2022
Nuvalent, Inc. announced new preclinical data supporting the potential best-in-class profile of NVL-655 – an ALK-selective inhibitor, and a "Trial in Progress" poster for the Phase 1/2 ARROS-1 study of NVL-520 – a ROS1-selective inhibitor.
-
Experts from U.S. health regulatory agencies have announced plans to conduct a clinical trial to assess the safety and efficacy of TPOXX (tecovirimat) as an antiviral for monkeypox.
-
Sigilon Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
8/4/2022
Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, reported financial results for the second quarter ended June 30, 2022 as well as certain other business highlights.
-
Data Showing MyMD Pharmaceuticals’ MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences
8/3/2022
MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), announced today the publication of data in the Journal of Gerontology: Biological Sciences (JGBS) from a pre-clinical study of MYMD-1® demonstrating four-fold greater improvements than rapamycin in delaying aging and extending the life of mice who began treatment at the human equivalent of 60 years of age.
-
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis APIE Selected for Oral Presentation at the International Workshop of Scleroderma Research
8/2/2022
APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary anti-fibrotic drugs that target the apelin receptor, presented results from in vitro and in vivo studies supporting the potential of APT-101 as a therapeutic for interstitial lung disease, including those cases associated with systemic sclerosis.
-
Marengo Therapeutics and Ipsen have entered into a strategic, multi-year partnership to usher two of Marengo’s precision T cell immuno-oncology candidates into the clinic.
-
Ashvattha Therapeutics Announces Preclinical Data at the 2022 AAIC Demonstrating its Hydroxyl Dendrimer-Based Imaging Agent [18F]OP-801 Can Detect Early-Stage Neuroinflammation with a Higher Sensitivity Than TSPO-PET
8/1/2022
Ashvattha Therapeutics announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer -based PET tracer, [18F]OP-801, can detect neuroinflammation via activated microglia and macrophages with higher sensitivity than translocator protein 18 kDa [TSPO]-PET, using [18F]GE180, an established and validated PET imaging approach, in a mouse model of Alzheimer’s Disease.
-
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Presents Preclinical Evidence of Combination Therapy Potential for Varoglutamstat in AD at AAIC 2022
7/31/2022
Vivoryon Therapeutics N.V. announced the presentation of preclinical data on the Company's N3pE amyloid-targeting molecules at the prestigious Alzheimer's Association International Conference in San Diego.
-
Akari Therapeutics Announces Positive Results from Recent Pre-Clinical Studies of Investigational PASylated® Nomacopan That Support the Potential to Advance Research Toward IND/IMPD for Clinical Trials in Geographic Atrophy
7/28/2022
Akari Therapeutics, Plc today announced positive results from recent pre-clinical studies on the tolerability and extended dose interval of long-acting PAS-nomacopan in development for geographic atrophy (GA) in dry age-related macular degeneration (dAMD).
-
Umoja Biopharma Presents New Preclinical Data at the 2022 iPSC Manufacturing Summit on Synthetic Receptor Enabled Differentiation
7/28/2022
Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo to treat patients with solid and hematologic malignancies, announced new data at the 2022 iPSC Manufacturing Summit held in Boston, Mass.
-
AKSO Announces Publication of Preclinical Data Demonstrating Engineered Soluble BCMA Decoy Receptor AB001 Effectively Inhibits Multiple Myeloma and Diffuse Large B Cell Lymphoma
7/27/2022
AKSO Biopharmaceutical, Inc. (“AKSO”), a global biopharmaceutical company with an innovative and comprehensive approach to treat cancer, autoimmune disease, and genetic disorder, announced the publication in the Journal of Experimental Medicine of preclinical data demonstrating that AKSO’s late preclinical stage molecule AB001 effectively inhibits growth of Multiple Myeloma (“MM”) and Diffuse Large B Cell Lymphoma (“DLBCL”) in mice.
-
IDEAYA Announces IDE397 Clinical Program Update and ctDNA Molecular Responses Demonstrating Tumor Pharmacodynamic Modulation
7/27/2022
IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical program updates for IDE397, an investigational, potential best-in-class, small molecule MAT2A inhibitor being evaluated in an ongoing Phase 1/2 clinical trial.
-
Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting
7/26/2022
Humacyte, Inc. announced results evaluating the use of the small-diameter Human Acellular Vessel for coronary artery bypass grafting in a non-human primate model.
-
Instylla announces positive results from preclinical studies of Embrace™ Hydrogel Embolic System in hemorrhage models
7/26/2022
Instylla, Inc. today announced two publications that evaluated the Embrace™ Hydrogel Embolic System (HES) in preclinical porcine hemorrhage models.
-
A study published this month in Science discusses data that may support a devious alter ego of T-cells present within colorectal cancers that appear to inhibit and promote tumor progression.
-
The announcement signals that the WHO now views the outbreak as significant enough that a coordinated global response is necessary to control it.
-
IAMA Therapeutics Announces Initiation of Preclinical Development Studies in Drug-resistant Epilepsy Under a Service Agreement with Psychogenics
7/25/2022
IAMA Therapeutics and PsychoGenics Inc., a leader in AI-enabled phenotypic drug discovery and preclinical CRO services, today announced that the companies have entered into a service agreement to identify the efficacy of novel drug candidates in drug-resistant epilepsy.
-
In a recent interview with BioSpace, Imagine Pharma CEO Ngoc Thai shared the vast potential posed by a polypeptide called IMG-1 to treat Type 1 diabetes.
-
Frontera Therapeutics closed on a Series B funding round worth $160 million and announced an IND approval by the FDA for rare genetic retinal disease
-
Avista Therapeutics inked a partnership deal with Swiss pharma giant Roche to develop AAV gene therapy vectors for eye diseases.